Literature DB >> 24185277

Generation of the first autosomal dominant osteopetrosis type II (ADO2) disease models.

Imranul Alam1, Amie K Gray2, Kang Chu2, Shoji Ichikawa2, Khalid S Mohammad2, Marta Capannolo3, Mattia Capulli3, Antonio Maurizi3, Maurizio Muraca4, Anna Teti5, Michael J Econs6, Andrea Del Fattore4.   

Abstract

Autosomal dominant osteopetrosis type II (ADO2) is a heritable osteosclerotic disorder dependent on osteoclast impairment. In most patients it results from heterozygous missense mutations in the chloride channel 7 (CLCN7) gene, encoding for a 2Cl(-)/1H(+) antiporter. By a knock-in strategy inserting a missense mutation in the Clcn7 gene, our two research groups independently generated mouse models of ADO2 on different genetic backgrounds carrying the homolog of the most frequent heterozygous mutation (p.G213R) in the Clcn7 gene found in humans. Our results demonstrate that the heterozygous model holds true presenting with higher bone mass, increased numbers of poorly resorbing osteoclasts and a lethal phenotype in the homozygous state. Considerable variability is observed in the heterozygous mice according with the mouse background, suggesting that modifier genes could influence the penetrance of the disease gene.
© 2013.

Entities:  

Keywords:  Autosomal dominant osteopetrosis; Chloride channel 7; Mouse model; Osteoclast; Osteopetrosis

Mesh:

Substances:

Year:  2013        PMID: 24185277      PMCID: PMC3889206          DOI: 10.1016/j.bone.2013.10.021

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  26 in total

1.  X-ray structure of a ClC chloride channel at 3.0 A reveals the molecular basis of anion selectivity.

Authors:  Raimund Dutzler; Ernest B Campbell; Martine Cadene; Brian T Chait; Roderick MacKinnon
Journal:  Nature       Date:  2002-01-17       Impact factor: 49.962

2.  Disease status in autosomal dominant osteopetrosis type 2 is determined by osteoclastic properties.

Authors:  Kang Chu; Richard Snyder; Michael J Econs
Journal:  J Bone Miner Res       Date:  2006-07       Impact factor: 6.741

3.  Loss of the chloride channel ClC-7 leads to lysosomal storage disease and neurodegeneration.

Authors:  Dagmar Kasper; Rosa Planells-Cases; Jens C Fuhrmann; Olaf Scheel; Oliver Zeitz; Klaus Ruether; Anja Schmitt; Mallorie Poët; Robert Steinfeld; Michaela Schweizer; Uwe Kornak; Thomas J Jentsch
Journal:  EMBO J       Date:  2005-02-10       Impact factor: 11.598

4.  Autosomal dominant osteopetrosis: clinical severity and natural history of 94 subjects with a chloride channel 7 gene mutation.

Authors:  Steven G Waguespack; Siu L Hui; Linda A Dimeglio; Michael J Econs
Journal:  J Clin Endocrinol Metab       Date:  2006-12-12       Impact factor: 5.958

5.  Molecular and clinical heterogeneity in CLCN7-dependent osteopetrosis: report of 20 novel mutations.

Authors:  Alessandra Pangrazio; Michael Pusch; Elena Caldana; Annalisa Frattini; Edoardo Lanino; Parag M Tamhankar; Shubha Phadke; Antonio Gonzalez Meneses Lopez; Paul Orchard; Ercan Mihci; Mario Abinun; Michael Wright; Kim Vettenranta; Ivo Bariae; Daniela Melis; Ilhan Tezcan; Clarisse Baumann; Franco Locatelli; Marco Zecca; Edwin Horwitz; Lamia Sfaihi Ben Mansour; Mirjam Van Roij; Paolo Vezzoni; Anna Villa; Cristina Sobacchi
Journal:  Hum Mutat       Date:  2010-01       Impact factor: 4.878

6.  Characterization of osteoclasts from patients harboring a G215R mutation in ClC-7 causing autosomal dominant osteopetrosis type II.

Authors:  Kim Henriksen; Jeppe Gram; Sophie Schaller; Bjarne H Dahl; Morten H Dziegiel; Jens Bollerslev; Morten A Karsdal
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

7.  Osteopetrosis. A genetic and epidemiological study.

Authors:  J Bollerslev
Journal:  Clin Genet       Date:  1987-02       Impact factor: 4.438

8.  Chloride channel ClCN7 mutations are responsible for severe recessive, dominant, and intermediate osteopetrosis.

Authors:  Annalisa Frattini; Alessandra Pangrazio; Lucia Susani; Cristina Sobacchi; Massimiliano Mirolo; Mario Abinun; Marino Andolina; Adrienne Flanagan; Edwin M Horwitz; Ercan Mihci; Luigi D Notarangelo; Ugo Ramenghi; Anna Teti; Johan Van Hove; Dragana Vujic; Terri Young; Alberto Albertini; Paul J Orchard; Paolo Vezzoni; Anna Villa
Journal:  J Bone Miner Res       Date:  2003-10       Impact factor: 6.741

9.  Clinical, genetic, and cellular analysis of 49 osteopetrotic patients: implications for diagnosis and treatment.

Authors:  A Del Fattore; B Peruzzi; N Rucci; I Recchia; A Cappariello; M Longo; D Fortunati; P Ballanti; M Iacobini; M Luciani; R Devito; R Pinto; M Caniglia; E Lanino; C Messina; S Cesaro; C Letizia; G Bianchini; H Fryssira; P Grabowski; N Shaw; N Bishop; D Hughes; R P Kapur; H K Datta; A Taranta; R Fornari; S Migliaccio; A Teti
Journal:  J Med Genet       Date:  2005-08-23       Impact factor: 6.318

10.  The G215R mutation in the Cl-/H+-antiporter ClC-7 found in ADO II osteopetrosis does not abolish function but causes a severe trafficking defect.

Authors:  Patrick Schulz; Johannes Werner; Tobias Stauber; Kim Henriksen; Klaus Fendler
Journal:  PLoS One       Date:  2010-09-07       Impact factor: 3.240

View more
  16 in total

1.  Genotyping, generation and proteomic profiling of the first human autosomal dominant osteopetrosis type II-specific induced pluripotent stem cells.

Authors:  Minglin Ou; Chunhong Li; Donge Tang; Wen Xue; Yong Xu; Peng Zhu; Bo Li; Jiansheng Xie; Jiejing Chen; Weiguo Sui; Lianghong Yin; Yong Dai
Journal:  Stem Cell Res Ther       Date:  2019-08-14       Impact factor: 6.832

2.  Interferon Gamma-1b Does Not Increase Markers of Bone Resorption in Autosomal Dominant Osteopetrosis.

Authors:  Erik A Imel; Ziyue Liu; Dena Acton; Melissa Coffman; Netsanet Gebregziabher; Yan Tong; Michael J Econs
Journal:  J Bone Miner Res       Date:  2019-05-13       Impact factor: 6.741

3.  Bone marrow transplantation as a therapy for autosomal dominant osteopetrosis type 2 in mice.

Authors:  Imranul Alam; Rita L Gerard-O'Riley; Dena Acton; Sara L Hardman; Madeline Murphy; Marta B Alvarez; Rachel J Blosser; Anthony Sinn; Edward F Srour; Melissa A Kacena; Michael J Econs
Journal:  FASEB J       Date:  2022-09       Impact factor: 5.834

4.  Clcn7F318L/+ as a new mouse model of Albers-Schönberg disease.

Authors:  J Caetano-Lopes; S G Lessard; S Hann; K Espinoza; K S Kang; K E Lim; D J Horan; H R Noonan; D Hu; R Baron; A G Robling; M L Warman
Journal:  Bone       Date:  2017-09-20       Impact factor: 4.626

5.  High-throughput screening of mouse gene knockouts identifies established and novel skeletal phenotypes.

Authors:  Robert Brommage; Jeff Liu; Gwenn M Hansen; Laura L Kirkpatrick; David G Potter; Arthur T Sands; Brian Zambrowicz; David R Powell; Peter Vogel
Journal:  Bone Res       Date:  2014-10-28       Impact factor: 13.567

6.  Novel CLCN7 mutation identified in a Han Chinese family with autosomal dominant osteopetrosis-2.

Authors:  Hao Deng; Dan He; Pengfei Rong; Hongbo Xu; Lamei Yuan; Liu Li; Qian Lu; Yi Guo
Journal:  Mol Pain       Date:  2016-06-20       Impact factor: 3.395

7.  Enhanced but hypofunctional osteoclastogenesis in an autosomal dominant osteopetrosis type II case carrying a c.1856C>T mutation in CLCN7.

Authors:  Xiang Chen; Kun Zhang; Janet Hock; Chunyu Wang; Xijie Yu
Journal:  Bone Res       Date:  2016-11-29       Impact factor: 13.567

8.  An Exploration of Charge Compensating Ion Channels across the Phagocytic Vacuole of Neutrophils.

Authors:  Juliet R Foote; Philippe Behe; Mathew Frampton; Adam P Levine; Anthony W Segal
Journal:  Front Pharmacol       Date:  2017-02-28       Impact factor: 5.810

9.  Autosomal dominant osteopetrosis associated with renal tubular acidosis is due to a CLCN7 mutation.

Authors:  Sian E Piret; Caroline M Gorvin; Anne Trinh; John Taylor; Stefano Lise; Jenny C Taylor; Peter R Ebeling; Rajesh V Thakker
Journal:  Am J Med Genet A       Date:  2016-08-19       Impact factor: 2.802

10.  Effective Small Interfering RNA Therapy to Treat CLCN7-dependent Autosomal Dominant Osteopetrosis Type 2.

Authors:  Mattia Capulli; Antonio Maurizi; Luca Ventura; Nadia Rucci; Anna Teti
Journal:  Mol Ther Nucleic Acids       Date:  2015-09-01       Impact factor: 10.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.